Cerba Research today announced it was awarded a five-year contract for Clinical Central Laboratory Services from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).
Cerba Research today announced it was awarded a five-year
contract for Clinical Central Laboratory Services from the National Institute
of Allergy and Infectious Diseases (NIAID), part of the U.S. National
Institutes of Health (NIH).
NIAID conducts and supports basic
and applied research to better understand, treat, and ultimately prevent
infectious, immunologic, and allergic diseases. Findings from this research are
vital to NIAID’s efforts to advance vaccines, drugs, and diagnostic tools to better
diagnose, prevent, and treat infectious diseases. Cerba Research will provide
clinical laboratory screening and safety testing for NIAID-supported clinical
trials within the infectious disease area.
“We are pleased to be recognized
for our depth and breadth of central and specialty lab solutions across the
globe to support NIAID. Through our innovative mindset, courageous people, and
our work in vaccines and treatments in the field of infectious diseases, we
understand the importance in bringing these to people. Hence, we are committed
to supporting the NIAID’s clinical research initiatives to improve health,”
said Mario Papillon, chief executive officer, Cerba Research.
About Cerba Research
Cerba Research is a leading healthcare
company with end-to-end drug development and diagnostic solutions to optimize
R&D drug productivity and commercialization. Providing early phase
research, clinical development through central laboratory and diagnostic
services, assay and biomarker development and validation. Cerba Research works
with government agencies, non-government organisations as well as pharma and
biotech organisations to change the shape of clinical development.
About NIH NIAID
The National Institute of Allergy
and Infectious Diseases (NIAID) conducts and supports basic and applied
research to better understand, treat, and ultimately prevent infectious,
immunologic, and allergic diseases. NIAID is composed of 7 research divisions:
the Division of AIDS; the Division of Allergy, Immunology, and Transplantation;
the Division of Clinical Research; the Division of Extramural Activities; the
Division of Intramural Research; the Division of Microbiology and Infectious
Diseases; and the Dale and Betty Bumpers Vaccine Research Center. NIAID
scientists conduct intramural research in laboratories located in Bethesda,
Rockville, and Frederick, Maryland, and in Hamilton, Montana. More information
on NIAID programs, committees, and initiatives can be found on NIAID’s web site
at www.niaid.nih.gov.